PATIENT
Keep track of
your cancer and
treatment results
with Guardant
Complete.
your cancer and
treatment results
with Guardant
Complete.
Guardant Complete is a range of liquid and tissue tests for patients with early-stage and advanced-stage cancer. The results of each test enable your
doctor to:
- Monitor your
cancer status.1 - Make treatment decisions.2
- See if your treatment is working or not.3
Explore Guardant Complete testing options.
Cancer ScreeningEarly‑Stage CancerAdvanced‑Stage Cancer
Guardant Shield™
Guardant Reveal™1,4-6 | |
---|---|
SUITABLE FOR | |
Stage II or III colorectal, breast, or lung cancer | |
LIQUID TEST | |
USES CANCER DNA FOR DETECTION | |
INFORMS TREATMENT DECISIONS | |
MEDICARE COVERAGE | |
Stage II or III colorectal cancer patients only | |
SWIPE TO REVEAL FULL CHART | |||
FDA-Approved Guardant360® CDx2,7 | Guardant360®8 | Guardant360 TissueNext™9 | Guardant360 Response™3,10 |
---|---|---|---|
SUITABLE FOR ANY SOLID TUMOR CANCER | |||
LIQUID TEST | |||
N/A | |||
USES CANCER DNA FOR DETECTION | |||
INFORMS TREATMENT DECISIONS | |||
MEDICARE COVERAGE | |||
N/A | |||
A liquid test is a minimally invasive blood draw that enables your doctor to frequently track your cancer status and quickly make treatment decisions.1,11
GUARDANT ACCESS & SUPPORT
Visit your myGuardant patient profile.
Get full access to each of your Guardant testing reports as soon as they’re
available—so you can see what your doctor sees.
To activate your account, visit patients.guardanthealth.com.
Guardant Access
helps
manage the billing process.
To enroll in the Guardant Access program, review and sign the test order
form provided by your doctor.
Checks your eligibility for financial assistance if needed. Helps manage the billing process with your insurance company. Handles your billing questions related
to Guardant Complete. Makes every attempt to contact you if your expected out-of-pocket expense exceeds $100.
Contact Guardant Complete Patient Support.
Reach us via phone at 855.698.8887 855.698.8887 or via email
at guardantaccess@guardanthealth.com.
References: 1. Backgrounder: Guardant Reveal™ liquid biopsy test. Guardant Health, Inc. Palo Alto, CA. 2. Guardant360® CDx Technical Information. Guardant Health, Inc. Palo Alto, CA. July 2021. 3. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842-1853. doi:10.1158/2159-8290.CD-20-0047 4. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586-5594. doi:10.1158/1078-0432.CCR-21-0410 5. Janni W, Huober J, Braun T, et al. Multiomic, plasma-only circulating tumor DNA (ctDNA) assay identifies breast cancer patients with minimal residual disease (MRD) and predicts distant recurrence. Poster presented at: American Association for Cancer Research Annual Meeting; April 8-13, 2022; Philadelphia, PA. Accessed November 1, 2022. https://doi.org/10.1158/1538-7445.AM2022-3403 6. Nagasaka M, Uddin MH, Al-Hallak MN, et al. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Mol Cancer. 2021;20(1):82. doi:10.1186/s12943-021-01371-1 7. FDA News Release. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test. August 7, 2020. Accessed October 31, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test 8. Guardant360® Assay Specifications. Guardant Health, Inc. Palo Alto, CA. 9. Guardant360 TissueNext™ Assay Specifications. Guardant Health, Inc. Palo Alto, CA. 10. Guardant360 Response: Guide to ordering Guardant360 Response. Guardant Health, Inc. Palo Alto, CA. 11. Cui W, Milner-Watts C, O’Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022;171:44-54. doi:10.1016/j.ejca.2022.05.012